Where does Eximo Medical Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Eximo Medical Ltd. ranks #19,750 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Eximo Medical Ltd. hold?

Eximo Medical Ltd. holds 14 US utility patents granted between 2017 and 2025, spanning 5 technology areas.

What is Eximo Medical Ltd.'s Innovation Score?

Eximo Medical Ltd. has an Innovation Score of 35.7 out of 100 (top 48% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Eximo Medical Ltd. focus on?

Eximo Medical Ltd.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 13 patents, ranking #1,352 of 7,127 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Eximo Medical Ltd.'s patent grant rate increasing or decreasing?

Eximo Medical Ltd.'s recent grant velocity is +125% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Eximo Medical Ltd.'s patents?

Eximo Medical Ltd.'s patents average 17.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Eximo Medical Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Eximo Medical Ltd.

USPTO PatentsView assignee record - 14 granted patents across 5 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Eximo ranks #19,750 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 5 technology areas.

#19,750
of 49,997 US assignees by volume: Top 48%
by Innovation Score (35.7/100): 17.4
avg claims per patent: +125%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19750 · Foreign Corporation #19,750 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #19,750/49,997
PHOTO-FINISH Eaton Protection…
CPC-NARROW A61B · 5 areas
INNOV-THIN 35.7/100
CLAIMS-RICH 17.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +125% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Eaton Protection Systems IP GmbH & Co. KG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Eximo’s 35.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (26%) Velocity 8.0 pts (22%) Breadth 7.9 pts (22%) Claim depth 10.5 pts (29%)

Qualcomm Incorporated · highest

85
Eximo Medical · this assignee

36
3D Lighting… · lowest

7

What this shows Eximo's Innovation Score is 35.7/100 (top 48% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Eximo?

Each dot is one of Eximo’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Eximo’s own 17.4 claims/patent is ABOVE the 17.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Eximo vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Eximo's grants concentrate

Eximo Medical Ltd. is a focused PatentsView assignee: 5 CPC subclasses with 92.9% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2021. By volume, Eximo sits between Evoca S.P.A. and EcoCatalytic Inc..

Eximo's three-year grant acceleration

Eximo Medical Ltd. shows 6 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Evoca S P A

14
Evolution Well Se…

14
Exablox

14
Exail

14
Extreme

14
Eyesmatch

14
Eaton Protection…

14
Ecocatalytic

14
Eximo Medical ◀

14

What this shows Eximo holds 14 patents at rank #19,726, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Eximo

By rank, the assignees closest to #19,726 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Eximo's primary technology class.

Eximo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 48% higher than 52% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Eximo Medical Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	14.3%
2019	2	14.3%
2020	2	14.3%
2021	1	7.1%
2023	2	14.3%
2024	4	28.6%
2025partial year	1	7.1%

Which technologies does Eximo Medical Ltd. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 13

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 4

H01S - Devices Using THE Process OF Light Amplification BY Stimulated Emission OF Radiation [LASER] TO Amplify OR Generate LIGHT; Devices Using Stimulated Emission OF Electromagnetic Radiation IN Wave Ranges Other Than Optical 4

G02B - Optical Elements, Systems OR Apparatus 4

G01J - Measurement OF Intensity, Velocity, Spectral Content, Polarisation, Phase OR Pulse Characteristics OF Infrared, Visible OR Ultraviolet LIGHT; COLORIMETRY; Radiation Pyrometry 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Eximo Medical Ltd.'s patent record in context - here's where to go next.

Eximo Medical Ltd.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 92.9% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #19,750 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Eximo Medical Ltd. against Evoca S.P.A., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.